## **Special Issue**

# Last Trends of Antileishmanial Drug Discovery and Development

## Message from the Guest Editors

Leishmaniasis is a zoonotic vector-borne disease caused by an intracellular protozoan parasite of the genus Leishmania. It is transmitted to animals and humans through the bite of infected phlebotomine sandflies, which is most diffused in Europe, Africa, Asia, and Latin America. Based on clinical findings, three main phenotypic categories of leishmaniasis are described in humans. The cutaneous/mucocutaneus form: mucosal form and visceral leishmaniasis. Dogs affected by leishmania infection present a form called viscerocutaneous for the presence of both skin lesions and involvement of internal organs. The primary goals of treatment against leishmania infection are to prevent mortality and morbidity. Anti-parasitic drugs are considered treatments for disease, but their toxicity, cost, and rising resistance limit the therapeutic resource. This Special Issue aims to publish original articles, reviews, and studies on the new potential drugs and new treatment strategies useful to treat and control human and animal leishmaniasis effectively.

#### **Guest Editors**

Prof. Dr. Annamaria Passantino

Department of Veterinary Sciences, University of Messina, Messina, Italy

Dr. Michela Pugliese

Department of Veterinary Sciences, University of Messina, Messina, Italy

## Deadline for manuscript submissions

closed (14 December 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/208109

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

